As Trump Takes Aim at Tylenol, Should You Buy, Sell, or Hold Parent Company Kenvue Stock’s Here?

Kenvue (KVUE) is grappling with significant regulatory and reputational challenges stemming from unsubstantiated claims by the Trump administration linking acetaminophen to autism, which has contributed to a 20% stock decline in 2025 and investor concerns over market share and litigation risk, alongside a Q2 2025 organic sales decline of 4.2%. New CEO Kirk Perry is implementing a four-point turnaround plan focused on operational simplification and improved execution, showing early progress in some brands and maintaining healthy gross margins. Despite a downward revision in 2025 guidance, analysts project long-term sales and EPS growth, with the stock trading below its historical P/E and an ongoing strategic review positioning Kenvue as a potential turnaround candidate.

Analysis

Kenvue (KVUE) is navigating a complex environment characterized by significant external pressures and an internal operational turnaround. The company faces a material reputational and regulatory headwind from the Trump administration's unsubstantiated claims linking acetaminophen to autism, directly threatening its flagship Tylenol brand and contributing to a 20% stock price decline in 2025. This political risk is compounded by recent operational weakness, evidenced by a 4.2% decline in organic sales in Q2 2025 and a reduction in adjusted EPS to $0.29 from $0.32 over the past year, prompting management to revise 2025 guidance to a low single-digit organic sales decline. However, a compelling turnaround narrative is emerging under new CEO Kirk Perry, whose four-point plan aims to simplify operations, improve execution, and optimize the portfolio of 115 brands. Despite the top-line pressure, Kenvue maintains strong fundamentals, including a 60.9% gross margin and 12 consecutive quarters of market share gains for Tylenol. The stock currently trades at a forward P/E of 16.1x, a discount to its historical average of 18.1x, while analyst consensus projects long-term growth in both sales and EPS, with an average price target of $22.30 suggesting potential upside from its current price of $17.24.

Key Decisions for Investors

• Investors should closely monitor the regulatory and reputational risks associated with acetaminophen, as any official government warning could severely impact sales of Tylenol and overall investor sentiment.
• The investment thesis is now heavily dependent on the execution of the new management's turnaround plan; therefore, tracking key performance indicators such as sequential improvements in organic sales, e-commerce growth, and progress on SKU simplification is critical.
• Given the stock's 20% decline and a forward P/E multiple below its historical average, the current valuation may present an attractive entry point for long-term investors who are confident in the new leadership's ability to execute and unlock value through the ongoing strategic review.